drugset / Trial / NCT00061919

Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer

NCT00061919

Phase 3 Completed 724 enrolled University College, London
RandomizedParallel-groupTriple-blindTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as carboplatin and etoposide use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin, etoposide, and thalidomide to see how well they work compared to carboplatin and etoposide in treating patients with limited- or extensive-stage small cell lung cancer.

Timeline

Start
2003-04
Primary completion
2007-02
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified Oral
Background Carboplatin Small molecule Intravenous
Background Etoposide Small molecule Intravenous

Indications